Cargando…

Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder

BACKGROUND: Sleep problems are common in adults with attention-deficit/hyperactivity disorder (ADHD). This analysis aimed to evaluate the impact of lisdexamfetamine dimesylate (LDX) on sleep quality in adults with ADHD. METHODS: This 4-week, phase 3, double-blind, forced-dose escalation study of adu...

Descripción completa

Detalles Bibliográficos
Autores principales: Adler, Lenard A, Goodman, David, Weisler, Richard, Hamdani, Mohamed, Roth, Thomas
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732626/
https://www.ncbi.nlm.nih.gov/pubmed/19650932
http://dx.doi.org/10.1186/1744-9081-5-34
_version_ 1782171062858940416
author Adler, Lenard A
Goodman, David
Weisler, Richard
Hamdani, Mohamed
Roth, Thomas
author_facet Adler, Lenard A
Goodman, David
Weisler, Richard
Hamdani, Mohamed
Roth, Thomas
author_sort Adler, Lenard A
collection PubMed
description BACKGROUND: Sleep problems are common in adults with attention-deficit/hyperactivity disorder (ADHD). This analysis aimed to evaluate the impact of lisdexamfetamine dimesylate (LDX) on sleep quality in adults with ADHD. METHODS: This 4-week, phase 3, double-blind, forced-dose escalation study of adults aged 18 to 55 years with ADHD randomized participants to receive placebo (n = 62), or 30 (n = 119), 50 (n = 117), or 70 (n = 122) mg/d LDX, taken once a day in the morning. The self-rated Pittsburgh Sleep Quality Index (PSQI) was administered at baseline and at week 4 to assess sleep quality. The PSQI global score assesses 7 sleep components (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction) each scored from 0 (no difficulty) to 3 (severe difficulty). RESULTS: The mean baseline PSQI global score was 5.8 for LDX and 6.3 for placebo (P = .19) indicating poor overall sleep quality. At endpoint, least squares (LS) mean change from baseline was -0.8 for LDX vs -0.5 for placebo (P = .33). The daytime functioning component showed significant improvement in LS mean change at endpoint for LDX compared with placebo (LDX -0.4 vs placebo 0.0, P = .0001). LS mean changes for the other 6 PSQI components did not significantly differ from placebo. Sleep-related treatment-emergent adverse events with an incidence ≥2% in the active treatment and placebo groups, respectively, were insomnia (19.3% and 4.8%), initial insomnia (5.0% and 3.2%), middle insomnia (3.6% and 0%), sleep disorder (0.6% and 3.2%), somnolence (0.3% and 3.2%), and fatigue (4.7% and 4.8%), and were generally mild or moderate in severity. CONCLUSION: For most subjects, LDX was not associated with an overall worsening of sleep quality and significantly improved daytime functioning in adults with ADHD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00334880
format Text
id pubmed-2732626
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27326262009-08-27 Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder Adler, Lenard A Goodman, David Weisler, Richard Hamdani, Mohamed Roth, Thomas Behav Brain Funct Research BACKGROUND: Sleep problems are common in adults with attention-deficit/hyperactivity disorder (ADHD). This analysis aimed to evaluate the impact of lisdexamfetamine dimesylate (LDX) on sleep quality in adults with ADHD. METHODS: This 4-week, phase 3, double-blind, forced-dose escalation study of adults aged 18 to 55 years with ADHD randomized participants to receive placebo (n = 62), or 30 (n = 119), 50 (n = 117), or 70 (n = 122) mg/d LDX, taken once a day in the morning. The self-rated Pittsburgh Sleep Quality Index (PSQI) was administered at baseline and at week 4 to assess sleep quality. The PSQI global score assesses 7 sleep components (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction) each scored from 0 (no difficulty) to 3 (severe difficulty). RESULTS: The mean baseline PSQI global score was 5.8 for LDX and 6.3 for placebo (P = .19) indicating poor overall sleep quality. At endpoint, least squares (LS) mean change from baseline was -0.8 for LDX vs -0.5 for placebo (P = .33). The daytime functioning component showed significant improvement in LS mean change at endpoint for LDX compared with placebo (LDX -0.4 vs placebo 0.0, P = .0001). LS mean changes for the other 6 PSQI components did not significantly differ from placebo. Sleep-related treatment-emergent adverse events with an incidence ≥2% in the active treatment and placebo groups, respectively, were insomnia (19.3% and 4.8%), initial insomnia (5.0% and 3.2%), middle insomnia (3.6% and 0%), sleep disorder (0.6% and 3.2%), somnolence (0.3% and 3.2%), and fatigue (4.7% and 4.8%), and were generally mild or moderate in severity. CONCLUSION: For most subjects, LDX was not associated with an overall worsening of sleep quality and significantly improved daytime functioning in adults with ADHD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00334880 BioMed Central 2009-08-03 /pmc/articles/PMC2732626/ /pubmed/19650932 http://dx.doi.org/10.1186/1744-9081-5-34 Text en Copyright © 2009 Adler et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Adler, Lenard A
Goodman, David
Weisler, Richard
Hamdani, Mohamed
Roth, Thomas
Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
title Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
title_full Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
title_fullStr Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
title_full_unstemmed Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
title_short Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
title_sort effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732626/
https://www.ncbi.nlm.nih.gov/pubmed/19650932
http://dx.doi.org/10.1186/1744-9081-5-34
work_keys_str_mv AT adlerlenarda effectoflisdexamfetaminedimesylateonsleepinadultswithattentiondeficithyperactivitydisorder
AT goodmandavid effectoflisdexamfetaminedimesylateonsleepinadultswithattentiondeficithyperactivitydisorder
AT weislerrichard effectoflisdexamfetaminedimesylateonsleepinadultswithattentiondeficithyperactivitydisorder
AT hamdanimohamed effectoflisdexamfetaminedimesylateonsleepinadultswithattentiondeficithyperactivitydisorder
AT roththomas effectoflisdexamfetaminedimesylateonsleepinadultswithattentiondeficithyperactivitydisorder